Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit M Oza

Showing results (61-70 of 250) with videos related to

Pageof 25
Sort By:
Frontiers in Oncology|June 1, 2016
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionKatherine Karakasis, Julia V Burnier, Valerie Bowering, et al.
Cancer|October 4, 2014
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancerVincent Castonguay, Michelle K Wilson, Ivan Diaz-Padilla, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2020
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatmentMichelle McMullen, Katherine Karakasis, Bienvenu Loembe, et al.
Current Oncology (Toronto, Ont.)|January 27, 2021
Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the LiteratureLawrence Kasherman, Jeffrey Doi, Katherine Karakasis, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic CancersAinhoa Madariaga, Gordon J S Rustin, Ronald J Buckanovich, et al.
Journal of Surgical Oncology|August 2, 2019
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA studyJacob Korach, Nicoletta Colombo, Cesar Mendiola, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 1, 2020
Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastasesLawrence Kasherman, Ainhoa Madariaga, Marjan Rouzbahman, et al.
The Lancet. Oncology|October 5, 2015
Discordance between the results and conclusions of ICON7 - Authors' replyAmit M Oza, Adrian D Cook, Richard Kaplan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 3, 2018
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA StudyFrédéric Selle, Nicoletta Colombo, Jacob Korach, et al.
BMC Cancer|November 10, 2006
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret HospitalJeremy Ho, Gregory R Pond, Colin Newman, et al.
Pageof 25

Showing results (61-70 of 250) with videos related to

Sort By:
Pageof 25
Frontiers in Oncology|June 1, 2016
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionKatherine Karakasis, Julia V Burnier, Valerie Bowering, et al.
Cancer|October 4, 2014
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancerVincent Castonguay, Michelle K Wilson, Ivan Diaz-Padilla, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2020
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatmentMichelle McMullen, Katherine Karakasis, Bienvenu Loembe, et al.
Current Oncology (Toronto, Ont.)|January 27, 2021
Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the LiteratureLawrence Kasherman, Jeffrey Doi, Katherine Karakasis, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic CancersAinhoa Madariaga, Gordon J S Rustin, Ronald J Buckanovich, et al.
Journal of Surgical Oncology|August 2, 2019
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA studyJacob Korach, Nicoletta Colombo, Cesar Mendiola, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 1, 2020
Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastasesLawrence Kasherman, Ainhoa Madariaga, Marjan Rouzbahman, et al.
The Lancet. Oncology|October 5, 2015
Discordance between the results and conclusions of ICON7 - Authors' replyAmit M Oza, Adrian D Cook, Richard Kaplan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 3, 2018
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA StudyFrédéric Selle, Nicoletta Colombo, Jacob Korach, et al.
BMC Cancer|November 10, 2006
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret HospitalJeremy Ho, Gregory R Pond, Colin Newman, et al.
Pageof 25